LYEL — Lyell Immunopharma, Inc.

Is LYEL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Lyell Immunopharma, Inc. (LYEL) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $9.26. The rating moved from Strong Oversold to Oversold on September 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Lyell Immunopharma is exposed to typical specialty-biotech dynamics: valuation and near-term moves hinge on clinical milestones and capital markets access. Sector-level support for late-stage biologics and visible insider/specialist interest in select names can enable financing or M&A optionality, but a broader risk-off backdrop, a cooling IPO window, and drug-pricing/payer pressure increase execution and commercial risk. Public financial detail was not provided, making cash runway and dilution sensitivity critical to monitor. Key near-term drivers are upcoming data milestones, any financing activity, and news on regulatory or payer developments. Given the information available, maintain a neutral posture and closely watch trial readouts, cash-burn disclosures, and any shifts in market or policy catalysts that would warrant revaluation.

Key factors

  • Pipeline and clinical-readout dependence: valuation and near-term moves are driven primarily by clinical data milestones and timing of readouts.
  • Sector investor appetite for late-stage biologics provides potential financing and M&A optionality for select biotech names.
  • Macro risk-off and IPO window cooling: current market caution reduces probability of favorable equity raises or large secondary demand in the near term.
  • Policy pressure on drug pricing and payer dynamics (Medicare negotiation/IRA) increases uncertainty around commercial pricing and uptake for future therapies.
  • Limited public financial details in the provided dataset; cash runway and dilution risk are key determinants of near-term capital strategy.
  • Manufacturing and cell-therapy scale-up complexity could affect timelines and cost structure versus competitors.

Risks

  • Clinical trial failure, delay or negative readouts that materially reduce valuation.
  • Short cash runway or need for dilutive financing in a risk-off market environment.
  • Downward pricing pressure and reimbursement restrictions driven by Medicare negotiation and payer cost containment.
  • Competitive advances from other cell therapies, biologics, or combination regimens that erode market opportunity.
  • Operational and manufacturing scale-up challenges for complex biologic/cell therapy products.
  • Regulatory setbacks or longer-than-expected approval timelines.
  • Low trading volumes and negative sentiment swings that amplify share-price volatility.

See today's live rating, score and targets

Members see the live hourly rating for LYEL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.